Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis
Open Access
- 1 July 2021
- journal article
- review article
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 21 (4) , 221-226
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysisThe Journal of Clinical Pharmacology, 2015
- Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKDJournal of the American Society of Nephrology, 2014
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEuropean Heart Journal, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarinInternational Journal of Nephrology and Renovascular Disease, 2009
- Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2009
- Vitamin K-dependent Proteins, Warfarin, and Vascular CalcificationClinical Journal of the American Society of Nephrology, 2008
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986